Key result
Omapatrilat 40 mg shows consistent blood pressure reduction and vasopeptidase inhibition across age and gender.
Why the study?
The effect of age and gender on the pharmacodynamics of omapatrilat was not established.
Does age or gender affect the pharmacodynamics and blood pressure response of a single oral dose of omapatrilat 40 mg in healthy volunteers?
Does age or gender affect the pharmacodynamics and blood pressure response of a single oral dose of omapatrilat 40 mg in healthy volunteers?
Initial dosing of omapatrilat for hypertension does not need to be adjusted based solely on age or gender.
Answers are grounded in this paper and cite their sources.
Supports no age- or gender-based dose adjustment for omapatrilat in healthy volunteers; leaves open confirmation in hypertensive patients.
Omapatrilat is the most clinically advanced member of a new class of cardiovascular drugs, vasopeptidase inhibitors. Omapatrilat is a single molecule that simultaneously inhibits neutral endopeptidase and angiotensin-converting enzyme, thus preserving vasodilator peptides and inhibiting production of the vasoconstrictor angiotensin II. In healthy male volunteers, omapatrilat decreased blood pressure while being generally well tolerated, with no serious adverse events. This study was undertaken to determine the effect of age and gender on the pharmacodynamics of omapatrilat. Healthy male or female volunteers between the ages of 18 and 80 were given a single oral dose of omapatrilat 40 mg. Neither age nor gender affected the vasopeptidase inhibition by omapatrilat. There were no differences between subject groups in the effect of omapatrilat on supine systolic, diastolic, or mean arterial blood pressure. Based on this study of healthy subjects, it can be concluded that it is not necessary to adjust the initial dose of omapatrilat for the treatment of hypertension based solely on age or gender.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2001) studied Healthy volunteers. Omapatrilat was evaluated on Vasopeptidase inhibition and effect on supine systolic, diastolic, or mean arterial blood pressure. A single 40 mg oral dose of omapatrilat showed no differences in vasopeptidase inhibition or blood pressure reduction across age or gender groups in healthy volunteers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: